PCBL Chemical Limited Q3 FY26 Earnings Call Summary

PCBL reported a challenging Q3 FY26, with consolidated EBITDA at ₹231 crores and carbon black volumes declining 2% YoY to 141,271 MT, primarily due to a 13% ...

Summary

PCBL Chemical Limited - Q3 FY 2026 Earnings Call Summary Tuesday, February 03, 2026 15:00 hrs India Time

Event Participants

Executives 4 Anand Kumar (Group Head, Investor Relations), Nilesh Koul (Managing Director), Pankaj Kedia (Executive Director, Investor Relations), Raj Gupta (Chief Financial Officer)

Analysts 6 Aditya Khetan (SMIFS Institutional Equities), Ashwini Singh (Santosh Finlease), Bharat Seth (Quest Investment Advisors), Disha (Sapphire Capital), Radha (B&K Securities), Sanil Jain (Ambit Capital), Sanjesh Jain (ICICI Securities), Shashank Kanodia (ICICI Securities), Suyash (Mangaldas Venichand)

Financials & KPIs

Metric Reported Commentary
Carbon Black Sales Volume 141,271 MT -2% YoY; impacted by a 13% decline in exports despite 6% domestic growth.
Consolidated Revenue ₹1,846 crores Impacted by lower international volumes and volatile market conditions.
Consolidated EBITDA ₹231 crores Lower YoY; Q3 EBITDA/ton stood at ₹13,800 due to negative operating leverage.
9M FY26 EBITDA/ton ₹15,300 Reflects margin pressure from crude volatility and trade barriers in the first half.
Power External Sales 125 MUs +33% YoY; supported by increased efficiency and generation capacity.
Specialty Sales Volume 16,700 MT +17% YoY; gaining traction in industrial coatings and semiconductor segments.
Net Debt Reduction ~₹400 crores 9M FY26 achievement; driven by working capital efficiency and inventory management.
Aquapharm Revenue ₹327 crores Faced headwinds in oil & gas and US tariff-related uncertainty.

Geographic & Segment Commentary

  • Domestic Market: Volume grew 6% YoY to 89,615 MT. Management expects robust single-digit growth (5-6%) driven by tyre industry investments and recent GST cuts improving affordability.
  • International Market: Export volumes fell 13% YoY to 51,656 MT due to US tariff uncertainty (50% rate) and inventory destocking. Management anticipates a rebound following the India-US trade deal reducing tariffs to 18%.
  • Specialty Carbon: Sales volume increased 17% YoY. Focus remains on high-margin grades for semiconductors, data centers, and AI applications, with a new 20,000 MTPA line pre-commissioning in Mundra.
  • Aquapharm (Specialty Chemicals): Performance was impacted by a 23% QoQ decline in oil & gas due to lower US rig counts. Green chelates (GLDA/IDS) are seeing new allocations from P&G and Henkel.

Company-Specific & Strategic Commentary

  • Cost Optimization Project: Launched a company-wide initiative targeting ₹200 crores in cumulative savings over two years. Focus areas include yield improvement (1-2% target), logistics, and procurement diversification.
  • Feedstock Diversification: Evaluating coal tar as an alternative to CBFS to reduce concentration risk and leverage a current price differential of ~$200/ton.
  • Battery Materials (Nanovace): 80-ton pilot plant for battery energy applications expected by March 2026. Management targets a ₹1,700 crore topline at full utilization from the planned 2,000-ton commercial plant.
  • Capacity Expansion: Commissioned 60,000 MTPA brownfield rubber black in Tamil Nadu; total capacity now 850,000 MTPA.

Guidance & Outlook

Metric Guidance / Outlook Commentary
EBITDA/ton ₹24,000 - ₹25,000 5-year target; driven by product mix shift and cost efficiencies.
Aquapharm Growth 20%+ Volume Growth FY27 Driven by new customer allocations (P&G/Henkel) and anti-dumping duties.
CAPEX FY26 ₹550 crores Reduced intensity as major brownfield projects conclude.
CAPEX FY27 < ₹400 crores Includes maintenance, Nanovace pilot, and Acetylene black plant.
PAT Target (FY29) ₹2,500 crores Long-term guidance maintained; supported by multi-chemistry diversification.

Risks & Constraints

Risk Context
Geopolitical/Trade Tariffs and trade barriers impacted Q3 exports significantly. While US/EU deals are positive, volatility in global trade policies remains a watch point.
Leadership Transition Recent resignation of Aquapharm CEO (Suresh Kalra) and onboarding of new MD (Nilesh Koul). Effective business continuity during integration is critical.
Global Demand Global carbon black industry utilization is currently ~75% vs. normal 80%. Pricing power is constrained until global utilization restores.

Q&A Highlights

US Tariff Impact

  • Question: How much volume was lost due to US tariffs? (Aditya Khetan)
  • Answer: Hard to quantify, but customers were unwilling to commit due to uncertainty. The effective tariff is now ~8-9% after offsets, which will improve competitiveness against Asian peers (Nilesh Koul).

Aquapharm Recovery

  • Question: Why has Aquapharm not ramped up as expected? (Aditya Khetan)
  • Answer: Impacted by seasonality and lower oil rig counts in the US. However, 30% capacity was recently added. New orders from P&G and potential anti-dumping duties on HEDP/ATMP from China provide strong tailwinds (Pankaj Kedia).

Nanovace Commercialization

  • Question: What is the timeline and revenue potential for Nanovace? (Suyash)
  • Answer: Pilot live by March 2026. Commercial plant (2,000 tons) by end of FY28. At full utilization (FY29/30), it can generate ₹1,700 crore revenue with 50% EBITDA margins (Nilesh Koul/Raj Gupta).

Cost Savings Target

  • Question: Can you elaborate on the ₹200 crore cost saving plan? (Radha)
  • Answer: Multifaceted project involving refractory changes for 1-2% yield gain, digital analytics for productivity, and logistics optimization. Pilots are finished; horizontal deployment starts now (Nilesh Koul).

Key Takeaway

PCBL reported a challenging Q3 FY26, with consolidated EBITDA at ₹231 crores and carbon black volumes declining 2% YoY to 141,271 MT, primarily due to a 13% slump in exports linked to US tariff uncertainty and global destocking. Despite these headwinds, domestic demand remained resilient (+6% YoY), and specialty black volumes grew 17%. The company has pivotally secured a reduction in US tariffs from 50% to 18% and is embarking on a rigorous ₹200 crore cost-optimization program. Strategically, PCBL is diversifying into battery materials with its Nanovace pilot and expanding Aquapharm’s reach through new contracts with P&G and Henkel. Management maintains a long-term PAT guidance of ₹2,500 crores by FY29, supported by a healthy net debt reduction of ₹400 crores in 9M FY26. Improved trade relations via new FTAs and stabilized crude prices are expected to drive a recovery in margins and export volumes starting Q1 FY27.

Want more insights like this?

Subscribe to get deep dives delivered to your inbox.

More Earnings Summaries

Explore more Q3 FY26 earnings call analyses: